Smoking Cessation - Pipeline Review, H1 2015
ReportsWeb.com has announced the addition of the “Smoking Cessation - Pipeline Review, H1 2015” this report provides an overview of the Smoking Cessation's therapeutic pipeline.
(EMAILWIRE.COM, June 24, 2017 ) This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/smoking-cessation-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172417/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
Aradigm Corporation
Arena Pharmaceuticals, Inc.
Astraea Therapeutics, LLC
Bioprojet SCR
Embera NeuroTherapeutics, Inc.
FORUM Pharmaceuticals Inc.
GlaxoSmithKline plc
Invion Limited
Johnson & Johnson
Marinus Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Pfizer Inc.
Royalty Pharma
Selecta Biosciences, Inc.
Targacept, Inc.
Zynerba Pharmaceuticals, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172417/discount
List of Tables
Number of Products under Development for Smoking Cessation, H1 2015 10
Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Investigation by Universities/Institutes, H1 2015 20
Smoking Cessation-Pipeline by Aradigm Corporation, H1 2015 21
Smoking Cessation-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22
Smoking Cessation-Pipeline by Astraea Therapeutics, LLC, H1 2015 23
Smoking Cessation-Pipeline by Bioprojet SCR, H1 2015 24
Smoking Cessation-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25
Smoking Cessation-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26
Smoking Cessation-Pipeline by GlaxoSmithKline plc, H1 2015 27
Smoking Cessation-Pipeline by Invion Limited, H1 2015 28
Smoking Cessation-Pipeline by Johnson & Johnson, H1 2015 29
Smoking Cessation-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30
Smoking Cessation-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31
Smoking Cessation-Pipeline by Pfizer Inc., H1 2015 32
Smoking Cessation-Pipeline by Royalty Pharma, H1 2015 33
Smoking Cessation-Pipeline by Selecta Biosciences, Inc., H1 2015 34
Smoking Cessation-Pipeline by Targacept, Inc., H1 2015 35
Smoking Cessation-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Assessment by Combination Products, H1 2015 38
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Smoking Cessation Therapeutics-Recent Pipeline Updates, H1 2015 78
Smoking Cessation-Dormant Projects, H1 2015 90
Smoking Cessation-Discontinued Products, H1 2015 91
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172417/buy/2000
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/smoking-cessation-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172417/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
Aradigm Corporation
Arena Pharmaceuticals, Inc.
Astraea Therapeutics, LLC
Bioprojet SCR
Embera NeuroTherapeutics, Inc.
FORUM Pharmaceuticals Inc.
GlaxoSmithKline plc
Invion Limited
Johnson & Johnson
Marinus Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Pfizer Inc.
Royalty Pharma
Selecta Biosciences, Inc.
Targacept, Inc.
Zynerba Pharmaceuticals, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172417/discount
List of Tables
Number of Products under Development for Smoking Cessation, H1 2015 10
Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Investigation by Universities/Institutes, H1 2015 20
Smoking Cessation-Pipeline by Aradigm Corporation, H1 2015 21
Smoking Cessation-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22
Smoking Cessation-Pipeline by Astraea Therapeutics, LLC, H1 2015 23
Smoking Cessation-Pipeline by Bioprojet SCR, H1 2015 24
Smoking Cessation-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25
Smoking Cessation-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26
Smoking Cessation-Pipeline by GlaxoSmithKline plc, H1 2015 27
Smoking Cessation-Pipeline by Invion Limited, H1 2015 28
Smoking Cessation-Pipeline by Johnson & Johnson, H1 2015 29
Smoking Cessation-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30
Smoking Cessation-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31
Smoking Cessation-Pipeline by Pfizer Inc., H1 2015 32
Smoking Cessation-Pipeline by Royalty Pharma, H1 2015 33
Smoking Cessation-Pipeline by Selecta Biosciences, Inc., H1 2015 34
Smoking Cessation-Pipeline by Targacept, Inc., H1 2015 35
Smoking Cessation-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Assessment by Combination Products, H1 2015 38
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Smoking Cessation Therapeutics-Recent Pipeline Updates, H1 2015 78
Smoking Cessation-Dormant Projects, H1 2015 90
Smoking Cessation-Discontinued Products, H1 2015 91
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172417/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results